Cogent Biosciences, Inc. balance sheet

At the end of fiscal 2020, Cogent Biosciences, Inc. had total assets of $251m, total liabilities of $16.2m and shareholders' equity of $235m. It held $242m in cash against $0 of debt: net cash of $242m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Cogent Biosciences, Inc.: balance sheet, annual
Fiscal year	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020
Cash and equivalents	28	56	37	242
Receivables	1	2	2	—
Total current assets	42	81	41	245
Total assets	49	86	49	251
Accounts payable	1	2	3	1
Deferred revenue (current)	7	18	1	—
Total current liabilities	11	25	13	13
Total debt	0	0	0	0
Total liabilities	21	26	18	16
Shareholders' equity	−49	60	32	235
Non-controlling interests and other (assets − liabilities − equity)	77	—	—	—
Net debt (negative = net cash)	−28	−56	−37	−242
Shares outstanding	—	—	8m	—

US$ millions unless shown otherwise. Fiscal quarters.

Cogent Biosciences, Inc.: balance sheet, quarterly
Quarter	2019 Q1Mar 2019	2019 Q2Jun 2019	2019 Q3Sept 2019	2019 Q4Dec 2019	2020 Q1Mar 2020	2020 Q2Jun 2020	2020 Q3Sept 2020	2020 Q4Dec 2020
Receivables	2	1	1	2	—	—	—	—
Total current assets	70	59	48	41	31	24	133	245
Total assets	81	69	58	49	39	31	140	251
Accounts payable	2	2	2	3	1	1	1	1
Deferred revenue (current)	17	15	15	1	1	0	—	—
Total current liabilities	26	24	24	13	9	8	20	13
Total liabilities	32	30	29	18	13	12	24	16
Shareholders' equity	49	40	29	32	26	19	−22	235
Non-controlling interests and other (assets − liabilities − equity)	—	—	—	—	—	—	138	—
Shares outstanding	30m	31m	31m	8m	31m	31m	11m	32m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Cogent Biosciences, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Cogent Biosciences, Inc.